Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Psychopharmacology
  4. Volume 12, Issue 1
  5. Article
Volume 12, Issue 1
  • ISSN: 2211-5560
  • E-ISSN: 2211-5579

Abstract

Background

Medication-assisted treatment constitutes the gold standard management for patients with opioid use disorder. Many factors can alter the response to medications, including genetic variations. In this case report, we discuss the presentation of a patient maintained on subcutaneous extended-release buprenorphine formulation who repeatedly presented objective and subjective signs of opioid withdrawal when he was switched from weekly to monthly formulation. We particularly highlight the role of metabolic pharmacogenes in this presentation.

Case Presentation

Mr. Y, a 31-year-old single man, presented to our rehabilitation center seeking assistance for his polysubstance dependence, mainly opioid use disorder. As part of his multidisciplinary treatment plan, he was started on weekly extended-release buprenorphine. After maintenance for several months, he was transitioned to the monthly equivalent formulation. Since the transition, he began to develop severe withdrawal symptoms 1-2 weeks before his next due injection. This was paralleled by a noted decrease in buprenorphine level on his urine drug screening test. As soon as the patient was placed back on the weekly formulation, his symptoms resolved.

Conclusion

This is a novel case highlighting the potential role of pharmacogenomics in clinical presentation and response to medications. Switching patients from weekly to monthly extended-release buprenorphine formulation might make rapid or ultra-rapid metabolizers at risk of early-onset withdrawal symptoms. In such a case, earlier provision of the injection or switching to another formulation or medication can be considered.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpsp/10.2174/0122115560292967240527072922
2024-05-31
2025-04-23

  • From This Site

    /content/journals/cpsp/10.2174/0122115560292967240527072922
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BahjiA. ChengB. GrayS. StuartH. Mortality among people with opioid use disorder: A systematic review and meta-analysis.J. Addict. Med.2020144e118e13210.1097/ADM.0000000000000606 32011406
     [Google Scholar]
  2. AlawaJ. MuhammadM. KazemitabarM. Medication for opioid use disorder in the Arab World: A systematic review.Int. J. Drug Policy202210210361710.1016/j.drugpo.2022.103617 35182841
     [Google Scholar]
  3. OesterleT.S. ThusiusN.J. RummansT.A. GoldM.S. Medication-assisted treatment for opioid-use disorder.Mayo Clin. Proc.201994102072208610.1016/j.mayocp.2019.03.029 31543255
     [Google Scholar]
  4. SofuogluM. DeVitoE.E. CarrollK.M. Pharmacological and behavioral treatment of opioid use disorder.Psychiatr. Res. Clin. Pract.20191141510.1176/appi.prcp.20180006
     [Google Scholar]
  5. National Academies of Sciences, Engineering, and Medicine Medications for opioid use disorder save lives.The National Academies PressWashington DC2019
     [Google Scholar]
  6. MaJ. BaoY.P. WangR.J. Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis.Mol. Psychiatry201924121868188310.1038/s41380‑018‑0094‑5 29934549
     [Google Scholar]
  7. PoliwodaS. NoorN. JenkinsJ.S. Buprenorphine and its formulations: A comprehensive review.Health Psychol. Res.20221033751710.52965/001c.37517 35999975
     [Google Scholar]
  8. BoyettB. NadipelliV.R. SolemC.T. ChilcoatH. BickelW.K. LingW. Continued posttrial benefits of buprenorphine extended release: Recover study findings.J. Addict. Med.202317218218910.1097/ADM.0000000000001070 36111991
     [Google Scholar]
  9. SeguíH A MelinK QuiñonesD S DucongeJ. A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder.J translat genet genom20204263277
     [Google Scholar]
  10. PirmohamedM. Pharmacogenomics: Current status and future perspectives.Nat. Rev. Genet.202324635036210.1038/s41576‑022‑00572‑8 36707729
     [Google Scholar]
  11. PardiñasA.F. OwenM.J. WaltersJ.T.R. Pharmacogenomics: A road ahead for precision medicine in psychiatry.Neuron2021109243914392910.1016/j.neuron.2021.09.011 34619094
     [Google Scholar]
  12. VentolaC L Role of pharmacogenomic biomarkers in predicting and improving drug response: Part 1: The clinical significance of pharmacogenetic variants.P & T. a peer-rev j formul manag2013389545560
     [Google Scholar]
  13. McDonnellA.M. DangC.H. Basic review of the cytochrome p450 system.J. Adv. Pract. Oncol.201344263268 25032007
     [Google Scholar]
  14. ElarabiH. ElrasheedA. AliA. Suboxone treatment and recovery trial (STAR-T): Study protocol for a randomised controlled trial of opioid medication assisted treatment with adjunctive medication management using therapeutic drug monitoring and contingency management.J. Addict.2019201911110.1155/2019/2491063 30956839
     [Google Scholar]
  15. European Medicines Agency. (2018). Buvidal Assessment report. Science Medicines Health.Available from: https://www.ema. europa.eu/en/documents/assessment-report/buvidal-epar-public-assessment-report_en.pdf
  16. TidderJ. Long-acting injectable buprenorphine (Buvidal®) protocol. NHS borders clinical guidelines. Retrieved on 20/10/2023. Available from: https://rightdecisions.scot.nhs.uk/nhs-borders-clinical-guidelines/mental-health-learning-disabilities/long-acting-injectable-buprenorphine-buvidal-protocol/
  17. KharidiaJ. HowgateE.M. LaffontC.M. LiuY. YoungM.A. Evaluation of drug‐drug interaction liability for buprenorphine extended‐release monthly injection administered by subcutaneous route.Clin. Pharmacol. Drug Dev.20211091064107410.1002/cpdd.934 33750027
     [Google Scholar]
  18. Al-AhmadM.M. AmirN. DhanasekaranS. Genetic polymorphisms of cytochrome P450-1A2 (CYP1A2) among Emiratis.PLoS One2017129e018342410.1371/journal.pone.0183424 28934216
     [Google Scholar]
  19. EttienneE.B. OfoegbuA. ManenoM.K. Pharmacogenomics and opioid use disorder: Clinical decision support in an african american cohort.J. Natl. Med. Assoc.2019111667468110.1016/j.jnma.2019.09.006 31676110
     [Google Scholar]
  20. LoA. KerrT. HayashiK. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs.J. Subst. Abuse Treat.201894414610.1016/j.jsat.2018.08.009 30243416
     [Google Scholar]
  21. WongA.K. SomogyiA.A. RubioJ. PhilipJ. The role of pharmacogenomics in opioid prescribing.Curr. Treat. Options Oncol.202223101353136910.1007/s11864‑022‑01010‑x 36001223
     [Google Scholar]
  22. RandesiM. RotrosenJ. NunesE.V. Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians.Am. J. Drug Alcohol Abuse202046676176810.1080/00952990.2020.1797064 32851876
     [Google Scholar]
  23. KranzlerH.R. LynchK.G. CristR.C. A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder.Int. J. Neuropsychopharmacol.2021242899610.1093/ijnp/pyaa069 32920647
     [Google Scholar]
  24. CristR.C. Vickers-SmithR. KemberR.L. Analysis of genetic and clinical factors associated with buprenorphine response.Drug Alcohol Depend.202122710901310.1016/j.drugalcdep.2021.109013 34488071
     [Google Scholar]
/content/journals/cpsp/10.2174/0122115560292967240527072922
Loading
Rapid Metabolism of Monthly Extended-Release Buprenorphine Formulation: A Case Report
Current Psychopharmacology 12, E310524230588 (2024); https://doi.org/10.2174/0122115560292967240527072922
/content/journals/cpsp/10.2174/0122115560292967240527072922
/content/journals/cpsp/10.2174/0122115560292967240527072922
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): Buprenorphine; case report; extended-release; medication-assisted treatment; opioid use disorder; rapid metabolism

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test